Pebezertinib

N/A

Report date: 2025/05/13 16:53:23
NME

Base Information

Drug NamePebezertinib
Drug Alias NameG8G5AU5GLJLNG-451BLU-451BLU-203139
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR exon 20 insertion mutations inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsEGFR exon 20 insertion mutationsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBrain metastasesLung DiseasesRespiratory Tract Diseases +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLengo Therapeutics IncBlueprint Medicines Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBlueprint Medicines Corp
Active IndicationsN/A
Inactive IndicationsBrain metastasesLung DiseasesRespiratory Tract Diseases +[11] 

Other Information

ATC CodeN/A
Related LinksN/A